US OptionsDetailed Quotes
ESPR250516C2000
- 0.05
- 0.000.00%
15min DelayClose Apr 30 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume202 Open Interest2.00Strike Price0.00Turnover285.28%IV105.21%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1949Delta0.4618Gamma19.99Leverage Ratio-0.0051Theta0.0001Rho3.90Eff Leverage0.0006Vega
Esperion Therapeutics Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$
I will Bet Anyone If you BUY This STOCK Now You Will Make 150% Minimum By Years End, with 800% Upside
Please get your Cholesterol level checked every 6 months, it is the #1 cause of DEATH.
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDA...
I will Bet Anyone If you BUY This STOCK Now You Will Make 150% Minimum By Years End, with 800% Upside
Please get your Cholesterol level checked every 6 months, it is the #1 cause of DEATH.
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDA...
9
1
$Esperion Therapeutics (ESPR.US)$ the analyst ratings in the news section is comical. from like 2 to 16 dollars. lol. shouldn't be that much of a discrepancy. analysts are useless
2
2
$Esperion Therapeutics (ESPR.US)$ this js good mews but a way off anythibg tangible yet - we have to how the quarterly briefing they strongly outline nearterm revenue growth for the cholesterol lowerong drug
lifesciencerepo...
lifesciencerepo...
2
1
$Esperion Therapeutics (ESPR.US)$ Follow Linkedin posts by Esperion. $Novartis AG (NVS.US)$ is connected. I expect to hear a Big partnership or acquistion. The stock price is extremely undervalued.
1
3
$Esperion Therapeutics (ESPR.US)$ time to sell
Please get your Cholesterol level checked every 6 months, it is the #1 cause of DEATH.
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDAQ: ESPR) looks like one of the most compelling—and misunderstood—opportunities in biotech. Despite having two FDA-approved drugs, expanding gl...
Why I’m Buying Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ in 2025: A Deeply Undervalued Biotech on the Edge of Profitability
Esperion Therapeutics (NASDAQ: ESPR) looks like one of the most compelling—and misunderstood—opportunities in biotech. Despite having two FDA-approved drugs, expanding gl...
+3
10
$Esperion Therapeutics (ESPR.US)$
always see such braggy articles,and always after them published,the stock price is down
always see such braggy articles,and always after them published,the stock price is down
1
$Esperion Therapeutics (ESPR.US)$
Esperion Therapeutics has been hammered down this year to an unrealistic valuation.
Esperion Therapeutics (ESPR) seems to be an unknown to many but is a fascinating story in the biotech world right now, particularly in the cardiovascular space. Despite its promising treatments and upcoming milestones, Esperion is currently trading at an extremely ...
Esperion Therapeutics has been hammered down this year to an unrealistic valuation.
Esperion Therapeutics (ESPR) seems to be an unknown to many but is a fascinating story in the biotech world right now, particularly in the cardiovascular space. Despite its promising treatments and upcoming milestones, Esperion is currently trading at an extremely ...
+1
18
1
1
Esperion Therapeutics: A CEO's Failure Is Holding Back a 10x Opportunity
Let’s be clear: Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ is not failing—its leadership is.
CEO Sheldon Koenig and CFO Ben Halladay have betrayed shareholder trust, mismanaged communications, and allowed short sellers to dominate the narrative while sitting on a goldmine of science, partnerships, and financial upside. Activists maybe ...
Let’s be clear: Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ is not failing—its leadership is.
CEO Sheldon Koenig and CFO Ben Halladay have betrayed shareholder trust, mismanaged communications, and allowed short sellers to dominate the narrative while sitting on a goldmine of science, partnerships, and financial upside. Activists maybe ...
10
2
1
No comment yet
72792912 : There are too many similar articles promoting this stock, but every time an article promoting it appears, the stock price follows by falling.